Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

Abstract Background Achieving control of glycated hemoglobin (HbA1c), blood pressure (BP), and body weight (BW) remains a challenge for most patients with type 2 diabetes mellitus (T2DM). In clinical trials, canagliflozin (CANA), an inhibitor of sodium-glucose co-transporter 2, has shown significant...

Full description

Bibliographic Details
Main Authors: Carol H. Wysham, Patrick Lefebvre, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Wing Chow, Michael Pfeifer, Mei Sheng Duh
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Endocrine Disorders
Subjects:
Canagliflozin
Type 2 diabetes mellitus
Dipeptidyl peptidase-4 inhibitor
HbA1c
Blood pressure
Weight loss
Online Access:http://link.springer.com/article/10.1186/s12902-017-0180-8

Internet

http://link.springer.com/article/10.1186/s12902-017-0180-8

Similar Items